|
|
 |
|
|
|
|
Factoid of the Day
|
Friday, December 14, 2018
|
|
The Food and Drug Administration (FDA) approved 55 new molecular entities (drugs) in the first 11 months of 2018, the most approvals ever for a calendar year, according to FierceBiotech. The previous all-time high for FDA drug approvals was 53 in 1996. The new drug pipeline is deep. In 2018, there were 7,201 Investigational New Drug (IND) applications on the FDA's books, up 25% from a decade ago. An IND is a request for authorization to administer an investigational drug or biological product to humans.
|
|
New ETFs – Listing Date: November 2, 2018
New ETF – Listing Date: November 6, 2018
|
| |
Unit Investment Trusts Upcoming Deposit Information |
Initial Offer Date |
| |
Click Here
for CUSIP Information.
|
| • |
Aerospace & Defense, 23 |
12/17/2018 |
| • |
Innovative Technology, 21 |
12/17/2018 |
| • |
Mega-Cap, 51 |
12/17/2018 |
| • |
Tax-Advantaged Municipal Closed-End, 55 |
12/17/2018 |
| • |
High-Yield Income Closed-End, 84 |
12/18/2018 |
| • |
Dow Jones Global Titans, 26 |
12/19/2018 |
| • |
Global Deep Value Dividend, 21 |
12/19/2018 |
| • |
Global Equity Income Closed-End, 62 |
12/19/2018 |
| • |
Richard Bernstein Advisors Global Dividend Kings®, 29 |
12/19/2018 |
| • |
Silicon Valley Opportunity, 2 |
12/19/2018 |
| • |
Interest Rate Hedge and ETF, 23 |
12/20/2018 |
| • |
Sabrient Baker's Dozen, December 2018 |
12/20/2018 |
| • |
AI, Robotics & Technology Opportunity, 6 |
12/21/2018 |
| • |
E-Commerce Opportunity, 6 |
12/21/2018 |
| • |
Innovative Transaction & Process, 4 |
12/21/2018 |
| • |
Nasdaq® Dividend Achievers 25, 14 |
12/21/2018 |
| • |
Sabrient Small Cap Growth, 21 |
12/21/2018 |
| • |
Strategic International Opportunity, 7 |
12/21/2018 |
| • |
Communication Services Opportunity, 2 |
12/28/2018 |
| • |
MLP Closed-End Fund and Energy, 62 |
12/28/2018 |
| • |
Municipal Income Select, Closed-End, 99 |
12/28/2018 |
| • |
Tactical Income Opportunity, 8 |
12/28/2018 |
| • |
FT Equity Allocation ETF Model, 1 Qtr 2019 |
1/3/2019 |
| • |
FT High Income Model, 1 Qtr 2019 |
1/3/2019 |
| • |
Diversified Equity Strategic Allocation, 1st Qtr 2019 |
1/9/2019 |
| • |
40/60 Strategic Allocation, 1st Qtr 2019 |
1/10/2019 |
| • |
60/40 Strategic Allocation, 1st Qtr 2019 |
1/10/2019 |
| • |
75/25 Strategic Allocation, 1st Qtr 2019 |
1/10/2019 |
| • |
Diversified Fixed Income ETF, 37 |
1/10/2019 |
| • |
Dow® Target 10, January 2019 |
1/10/2019 |
| • |
Dow® Target 5, 1st Qtr 2019 |
1/10/2019 |
| • |
Dow® Target Dividend, 1st Qtr 2019 |
1/10/2019 |
| • |
European Target High Quality Dividend, 1st Qtr 2019 |
1/10/2019 |
| • |
Global Target 15, 1st Qtr 2019 |
1/10/2019 |
| • |
Income Allocation Closed-End, 1st Qtr 2019 |
1/10/2019 |
| • |
S&P Dividend Aristocrats Target 25, 1st Qtr 2019 |
1/10/2019 |
| • |
S&P Target 24, 1st Qtr 2019 |
1/10/2019 |
| • |
S&P Target SMid 60, 1st Qtr 2019 |
1/10/2019 |
| • |
Target Diversified Dividend, 1st Qtr 2019 |
1/10/2019 |
| • |
Target Diversified Global Allocation, 1st Qtr 2019 |
1/10/2019 |
| • |
Target Dividend Blend, 1st Qtr 2019 |
1/10/2019 |
| • |
Target Dividend Double Play, 1st Qtr 2019 |
1/10/2019 |
| • |
Target Double Play, 1st Qtr 2019 |
1/10/2019 |
| • |
Target Focus Four, 1st Qtr 2019 |
1/10/2019 |
| • |
Target Global Dividend Leaders, 1st Qtr 2019 |
1/10/2019 |
| • |
Target Growth, 1st Qtr 2019 |
1/10/2019 |
| • |
Target High Quality Dividend, 1st Qtr 2019 |
1/10/2019 |
| • |
Target Triad, 1st Qtr 2019 |
1/10/2019 |
| • |
Target VIP, 1st Qtr 2019 |
1/10/2019 |
| • |
Value Line® Target 25, 1st Qtr 2019 |
1/10/2019 |
| • |
Value Line® Target Safety 30, 1st Qtr 2019 |
1/10/2019 |
| • |
Select DSIP, 1st Qtr 2019 |
1/14/2019 |
| • |
ETF Growth and Income, January 2019 |
1/15/2019 |
| • |
Inflation Hedge, 40 |
1/15/2019 |
| • |
Senior Loan Closed-End and ETF, 25 |
1/17/2019 |
|
| First Trust Mobile |
 | Get the latest First Trust product and research information on your smartphone or tablet device!
Learn more... |
|
|
|
|
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA and the Internal Revenue Code. First Trust has no knowledge of and has not been provided any information regarding any investor. Financial advisors must determine whether particular investments are appropriate for their clients. First Trust believes the financial advisor is a fiduciary, is capable of evaluating investment risks independently and is responsible for exercising independent judgment with respect to its retirement plan clients.
|